Fig. 3. Rhizoxin shortens the posterior ends of CRK1+CRK2-deficient procyclic-form cells. Rhizoxin (1 nM) was added to the CRK1+CRK2-deficient procyclic-form cells at the same time as tetracycline. The cells were cultured for 5 days, collected and stained with DAPI, YL1/2 antibody (A) and MitotrackerTM Green FM (B).